GH Research (NASDAQ:GHRS) Trading Down 2.6%

GH Research PLC (NASDAQ:GHRS) was down 2.6% on Wednesday . The company traded as low as $11.45 and last traded at $11.60. Approximately 11,034 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 103,062 shares. The stock had previously closed at $11.91.

Analyst Ratings Changes

Several analysts have commented on the company. Canaccord Genuity Group increased their target price on GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Tuesday, May 7th.

GH Research Price Performance

The stock has a market capitalization of $626.96 million, a P/E ratio of -19.21 and a beta of 0.86. The business’s 50 day moving average price is $12.32 and its 200 day moving average price is $9.69.

GH Research (NASDAQ:GHRS) last posted its earnings results on Friday, May 3rd. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. As a group, analysts forecast that GH Research PLC will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

Institutional investors have recently made changes to their positions in the business. AdvisorShares Investments LLC grew its holdings in GH Research by 4.3% during the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of GH Research by 14.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after buying an additional 13,579 shares during the period. RA Capital Management L.P. lifted its position in shares of GH Research by 11.9% during the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after buying an additional 664,381 shares in the last quarter. BVF Inc. IL grew its stake in shares of GH Research by 12.1% during the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after acquiring an additional 1,125,000 shares during the period. Finally, RTW Investments LP increased its holdings in GH Research by 53.4% in the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after acquiring an additional 1,158,172 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).